AUL
BBIO icon

AlphaGrep UK Ltd’s BridgeBio Pharma BBIO Stock Holding History

AlphaGrep UK Ltd’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224K Sell
3,010
-710
-19% -$51.5K 0.06% 671
2025
Q4 		$285K Buy
+3,720
New +$244K 0.1% 461

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaGrep UK Ltd's BBIO Position: Q1 2026 in Review

AlphaGrep UK Ltd reduced its BridgeBio Pharma (BBIO) stake by 19% in Q1 2026, selling an estimated $51.5K and leaving 3,010 shares worth $224K. The position accounts for 0.06% of the portfolio, ranked #671.

AlphaGrep UK Ltd first reported a position in BBIO in Q4 2025 and has held it in 2 quarters since. The position peaked at $285K in Q4 2025. 459 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • AlphaGrep UK Ltd held 3,010 shares of BridgeBio Pharma worth $224K as of Q1 2026.
  • AlphaGrep UK Ltd sold 710 BridgeBio Pharma shares in Q1 2026, an estimated $51.5K.
  • BridgeBio Pharma made up 0.06% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #671 holding.
  • AlphaGrep UK Ltd first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 2 quarters since.
  • AlphaGrep UK Ltd's BridgeBio Pharma position peaked at $285K in Q4 2025.
  • 459 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.